IBDEI2NB ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44401,0)
 ;;=D05.10^^200^2228^91
 ;;^UTILITY(U,$J,358.3,44401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44401,1,3,0)
 ;;=3^Intraductal Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,44401,1,4,0)
 ;;=4^D05.10
 ;;^UTILITY(U,$J,358.3,44401,2)
 ;;=^5001929
 ;;^UTILITY(U,$J,358.3,44402,0)
 ;;=D50.0^^200^2228^92
 ;;^UTILITY(U,$J,358.3,44402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44402,1,3,0)
 ;;=3^Iron Deficiency Anemia Secondary to Blood Loss
 ;;^UTILITY(U,$J,358.3,44402,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,44402,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,44403,0)
 ;;=D50.9^^200^2228^93
 ;;^UTILITY(U,$J,358.3,44403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44403,1,3,0)
 ;;=3^Iron Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,44403,1,4,0)
 ;;=4^D50.9
 ;;^UTILITY(U,$J,358.3,44403,2)
 ;;=^5002283
 ;;^UTILITY(U,$J,358.3,44404,0)
 ;;=C46.9^^200^2228^94
 ;;^UTILITY(U,$J,358.3,44404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44404,1,3,0)
 ;;=3^Kaposi's Sarcoma,Unspec
 ;;^UTILITY(U,$J,358.3,44404,1,4,0)
 ;;=4^C46.9
 ;;^UTILITY(U,$J,358.3,44404,2)
 ;;=^5001108
 ;;^UTILITY(U,$J,358.3,44405,0)
 ;;=C22.0^^200^2228^95
 ;;^UTILITY(U,$J,358.3,44405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44405,1,3,0)
 ;;=3^Liver Cell Carcinoma
 ;;^UTILITY(U,$J,358.3,44405,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,44405,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,44406,0)
 ;;=D05.02^^200^2228^96
 ;;^UTILITY(U,$J,358.3,44406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44406,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Left Breast
 ;;^UTILITY(U,$J,358.3,44406,1,4,0)
 ;;=4^D05.02
 ;;^UTILITY(U,$J,358.3,44406,2)
 ;;=^5001928
 ;;^UTILITY(U,$J,358.3,44407,0)
 ;;=D05.01^^200^2228^97
 ;;^UTILITY(U,$J,358.3,44407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44407,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Right Breast
 ;;^UTILITY(U,$J,358.3,44407,1,4,0)
 ;;=4^D05.01
 ;;^UTILITY(U,$J,358.3,44407,2)
 ;;=^5001927
 ;;^UTILITY(U,$J,358.3,44408,0)
 ;;=D05.00^^200^2228^98
 ;;^UTILITY(U,$J,358.3,44408,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44408,1,3,0)
 ;;=3^Lobular Carcinoma in Situ,Unspec Breast
 ;;^UTILITY(U,$J,358.3,44408,1,4,0)
 ;;=4^D05.00
 ;;^UTILITY(U,$J,358.3,44408,2)
 ;;=^5001926
 ;;^UTILITY(U,$J,358.3,44409,0)
 ;;=R59.0^^200^2228^59
 ;;^UTILITY(U,$J,358.3,44409,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44409,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Localized
 ;;^UTILITY(U,$J,358.3,44409,1,4,0)
 ;;=4^R59.0
 ;;^UTILITY(U,$J,358.3,44409,2)
 ;;=^5019529
 ;;^UTILITY(U,$J,358.3,44410,0)
 ;;=C83.59^^200^2228^99
 ;;^UTILITY(U,$J,358.3,44410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44410,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,44410,1,4,0)
 ;;=4^C83.59
 ;;^UTILITY(U,$J,358.3,44410,2)
 ;;=^5001590
 ;;^UTILITY(U,$J,358.3,44411,0)
 ;;=C83.50^^200^2228^100
 ;;^UTILITY(U,$J,358.3,44411,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44411,1,3,0)
 ;;=3^Lymphoblastic Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,44411,1,4,0)
 ;;=4^C83.50
 ;;^UTILITY(U,$J,358.3,44411,2)
 ;;=^5001581
 ;;^UTILITY(U,$J,358.3,44412,0)
 ;;=C43.9^^200^2228^102
 ;;^UTILITY(U,$J,358.3,44412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44412,1,3,0)
 ;;=3^Malig Melanoma of Skin,Unspec Site
 ;;^UTILITY(U,$J,358.3,44412,1,4,0)
 ;;=4^C43.9
 ;;^UTILITY(U,$J,358.3,44412,2)
 ;;=^5001015
 ;;^UTILITY(U,$J,358.3,44413,0)
 ;;=C31.9^^200^2228^103
 ;;^UTILITY(U,$J,358.3,44413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44413,1,3,0)
 ;;=3^Malig Neop Accessory Sinus,Unspec
 ;;^UTILITY(U,$J,358.3,44413,1,4,0)
 ;;=4^C31.9
